A Look At Roivant Sciences (ROIV) Valuation As IMVT-1402 And Earnings Outlook Draw Investor Focus

Simply Wall St.05-19 23:20

Recent commentary around Roivant Sciences (ROIV) has focused on two catalysts: increasing attention on its IMVT-1402 program in myasthenia gravis, and the company’s upcoming Q4 2026 earnings report on...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636687218?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-05-19 23:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636687218","market":"hk","top_or_hot":-1,"title":"A Look At Roivant Sciences (ROIV) Valuation As IMVT-1402 And Earnings Outlook Draw Investor Focus","media":"Simply Wall St.","content":"<div>\n<p>Recent commentary around Roivant Sciences (ROIV) has focused on two catalysts: increasing attention on its IMVT-1402 program in myasthenia gravis, and the company’s upcoming Q4 2026 earnings report on...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/a-look-at-roivant-sciences-roiv-valuation-as-imvt-1402-and-e\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Roivant Sciences (ROIV) Valuation As IMVT-1402 And Earnings Outlook Draw Investor Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Roivant Sciences (ROIV) Valuation As IMVT-1402 And Earnings Outlook Draw Investor Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-19 23:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/a-look-at-roivant-sciences-roiv-valuation-as-imvt-1402-and-e><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recent commentary around Roivant Sciences (ROIV) has focused on two catalysts: increasing attention on its IMVT-1402 program in myasthenia gravis, and the company’s upcoming Q4 2026 earnings report on...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/a-look-at-roivant-sciences-roiv-valuation-as-imvt-1402-and-e\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROIV","symbol_name":"Roivant Sciences Ltd.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/a-look-at-roivant-sciences-roiv-valuation-as-imvt-1402-and-e","article_id":"2636687218","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/a-look-at-roivant-sciences-roiv-valuation-as-imvt-1402-and-e","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2636687218","pubTimestamp":1779204005,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent commentary around Roivant Sciences (ROIV) has focused on two catalysts: increasing attention on its IMVT-1402 program in myasthenia gravis, and the company’s upcoming Q4 2026 earnings report on May 20.\nSee our latest analysis for Roivant Sciences.\nAt a share price of $28.55, Roivant has seen short term share price pressure, with the 1 day and 30 day share price returns both down. At the same time, a 90 day share price return of 5.39% and a 1 year total shareholder return of 163.38%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ROIV":"Roivant Sciences Ltd.","IMVT":"Immunovant, Inc."},"translate_title":"IMVT-1402的Roivant Sciences(ROIV)估值和盈利前景引起投资者关注","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMVT":1.5,"ROIV":1.5},"content_text":"Recent commentary around Roivant Sciences (ROIV) has focused on two catalysts: increasing attention on its IMVT-1402 program in myasthenia gravis, and the company’s upcoming Q4 2026 earnings report on May 20. See our latest analysis for Roivant Sciences. At a share price of $28.55, Roivant has seen short term share price pressure, with the 1 day and 30 day share price returns both down. At the same time, a 90 day share price return of 5.39% and a 1 year total shareholder return of 163.38% indicate momentum that has developed over a longer period. If you are watching Roivant around its upcoming results and MG program updates, this can be a useful moment to scan for other healthcare AI opportunities using our 31 healthcare AI stocks With Roivant trading at $28.55, sitting at a sizeable modelled intrinsic discount and below some analyst targets despite past share price strength, investors may ask whether there is still an entry point here or whether the market is already pricing in future growth. AdvertisementMost Popular Narrative: 20% Undervalued Roivant’s most followed narrative pegs fair value at $35.67 per share compared with the latest close at $28.55, putting valuation assumptions firmly under the microscope.  Roivant's late-stage pipeline, with potential approvals expected in the next couple of years, could lead to a projected $10 billion+ peak sales portfolio, significantly impacting earnings as these therapies are commercialized. Business development activities with negotiations for potential in-licensing of new programs are ongoing, representing opportunities for revenue growth through the expansion of their development-stage clinical pipeline.  Read the complete narrative. Want to see what is built into that pipeline story? Revenue expansion, margin reset, and a punchy earnings multiple sit at the core of this fair value case. Result: Fair Value of $35.67 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this story still carries real execution risk, with complex late stage trials and ongoing LNP litigation both capable of undermining the current fair value case. Find out about the key risks to this Roivant Sciences narrative. Another Angle On Valuation There is a twist when you shift from that fair value narrative to how the stock is priced on book value today. Roivant trades on a P/B of 4.8x, compared with 2.4x for the broader US biotech industry and 2.1x for peers, which clearly prices in a richer outlook and leaves less room if expectations cool. For a closer look at how this price tag stacks up against fundamentals and peers, check the valuation breakdown in our See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ROIV P/B Ratio as at May 2026Next Steps With mixed signals across valuation, pipeline potential and litigation risk, this is a moment to move quickly and review the full picture for yourself so you can weigh both the upside and the red flags in context using our 3 key rewards and 1 important warning sign Looking for more investment ideas? If Roivant is already on your radar, do not stop there. The next strong addition to your watchlist could be hiding in plain sight.  Spot potential bargains early by scanning 52 high quality undervalued stocks that pair supportive fundamentals with prices that may not fully reflect their current profiles. Strengthen your income stream by checking out 12 dividend fortresses built around higher yield opportunities that still focus on resilience. Prioritize resilience and sleep easier by reviewing 65 resilient stocks with low risk scores that aim to keep volatility and financial stress in check.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636687218","isCrawlerRequest":true}